Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 552,023
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone: 415-670-2000
hegdaom
hegdaom May. 13 at 1:15 AM
$CAPR shorts? time to reload before you get liquidated again!!!! $XBI $IBB
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle May. 12 at 4:49 PM
Makari resigning Tuesday https://www.google.com/url?q=https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014&sa=U&ved=2ahUKEwi-_YylmrSUAxU4hIkEHZLXMx0QFnoECAkQAg&usg=AOvVaw1F8xpU5WBva0-aBGc8elg- $IBB $XBI $KNSA
0 · Reply
flabb
flabb May. 12 at 1:51 PM
$IBB limit orders in 168.28 and 167.72
0 · Reply
hegdaom
hegdaom May. 12 at 1:29 AM
0 · Reply
macroaxis
macroaxis May. 11 at 10:42 PM
$IBB — Option volatility signal: iShares Biotechnology pin risk is easing. https://www.macroaxis.com/stock-options/IBB/iShares-Biotechnology-ETF?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
ripztrip
ripztrip May. 11 at 6:37 PM
$IDYA WHY the Lag Exists Several factors explain why the stock hasn't yet priced in the full upside despite bullish data: Topline ≠ Full Data: The April 13 release was just topline PFS data. The ASCO presentation on June 1 will deliver depth-of-response, subgroup analyses, durability, and safety granularity — details that regulators and physicians need, and that drive NDA filings. "Buy the rumor, sell the news" risk: Some traders may have taken gains after the April 13 pop, creating a reset opportunity before ASCO $XBB $IBB
2 · Reply
PickAlpha
PickAlpha May. 11 at 11:59 AM
3/6: MoonLake (MLTX) reports positive final pre‑BLA FDA meeting for sonelokimab (SLK) in hidradenitis suppurativa; plans BLA submission end‑Sep 2026 and seeks Priority Review. $MLTX $XBI $IBB $REGN $VRTX
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 11 at 3:26 AM
$VERA valuation & revenue multiples v 17 peer commercial-stage bios acquired just before/after FDA approval. The average peer 5-year revenue multiple was 1.35X &/or a 0.37X 10-year multiple. If VERA analyst consensus revenue estimates are credible AND if VERA were worth ab average 5 & 10-year multiples consistent with the 17 peers (2 HUGE IFs) that would come to $4.2-$4.4B in enterprise value. Adding VERA's $500MM net cash/debt would be $4.7-$4.9B in market cap. Using VERA's 3/31/26 cap table, that would come to $59-$62 per fully diluted share. This is a simple "what-if" as we're trying to learn more. Just to be clear, we have no idea what VERA might be worth in an acquisition. We also are unaware if VERA's gross margin profile will be consistent with these peers. This is not investment advice. Can any VERA investor comment on Atacicept's projected gross margin profile (as a subq injection) &/or speculate on whether or not VERA could fetch a premium M&A revenue multiple? $XBI $IBB
2 · Reply
BluntForceOptions
BluntForceOptions May. 11 at 12:21 AM
$IBB Q2 2026 Biotech Catalyst Outlook: 88 Major Data Readouts & Regulatory Milestones We're heading into a serious density of clinical data. If you’re in the trenches with these clinical-stage names, you know the next two months are essentially a gauntlet of binary events. The schedule is packed: 88 total catalysts, including 26 for May and 20 for June. I’m sharing this for those interested in a clear view of the upcoming calendar. It’s not an exhaustive list of every micro-cap ticker, but it covers the heart of the sector's upcoming volume. FWIW... trading this sector successfully requires looking past the mainstream narratives. I find it’s best to ignore the surface-level chatter and stick to a disciplined process of clinical and fundamental due diligence. Respect to everyone grinding through the data. Wishing you all the best... may your discipline be rewarded with the outcomes you’ve worked so hard to achieve. 🙏🏻 $XBI $CYTK $PFE $LLY - Source data: BiopharmIQ
0 · Reply
hegdaom
hegdaom May. 10 at 11:10 PM
$CAPR The near-term fight: Preliminary Injunction Capricor filed both its complaint and a preliminary injunction brief on May 7, 2026. This is the critical near-term battleground. In New Jersey Chancery (where the case was filed), preliminary injunction hearings are typically scheduled within a few weeks to a couple of months. Given the urgency — the FDA PDUFA date is August 22, 2026 — Capricor will argue strenuously for an expedited hearing. If the court grants the injunction before that date, Capricor could potentially distribute the drug on its own pending the full trial $XBI $IBB
0 · Reply
Latest News on IBB
Funding for Risky Biotechs Is Returning

Jan 12, 2026, 12:00 PM EST - 4 months ago

Funding for Risky Biotechs Is Returning

XBI


'Fast Money' traders talk how to play biopharma space

Nov 11, 2025, 6:56 PM EST - 6 months ago

'Fast Money' traders talk how to play biopharma space

XLV


Trade Tracker: Jason Snipe buys the IBB

Oct 17, 2025, 1:30 PM EDT - 7 months ago

Trade Tracker: Jason Snipe buys the IBB


Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

Jul 9, 2025, 11:09 AM EDT - 10 months ago

Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

CPER XBI


Fast Money: WTI, IBB, UBER, CAT

Jun 13, 2025, 6:20 PM EDT - 11 months ago

Fast Money: WTI, IBB, UBER, CAT

UBER CAT


New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 1 year ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK SRPT XBI


Sell into strength in pharma, says Mizuho's Jared Holz

Apr 11, 2025, 7:17 PM EDT - 1 year ago

Sell into strength in pharma, says Mizuho's Jared Holz

XBI


Final Trade: Euro, IBB, SMH, NEM

Nov 20, 2024, 6:21 PM EST - 1 year ago

Final Trade: Euro, IBB, SMH, NEM

SMH NEM


Analyst is 'extremely bullish' on biopharma

Jul 30, 2024, 3:25 PM EDT - 1 year ago

Analyst is 'extremely bullish' on biopharma

MRK PFE


Biotech's Next Gold Rush: Weight-Loss Drugs

Apr 2, 2024, 4:56 PM EDT - 2 years ago

Biotech's Next Gold Rush: Weight-Loss Drugs

LLY NVO


Navigating the big run in biotech

Feb 15, 2024, 1:44 PM EST - 2 years ago

Navigating the big run in biotech

XBI


Dr. Scott Gottlieb talks Big Pharma's buying spree

Dec 27, 2023, 4:26 PM EST - 2 years ago

Dr. Scott Gottlieb talks Big Pharma's buying spree

XBI


Wedbush's Laura Chico talks biotech investing in 2024

Dec 26, 2023, 5:21 PM EST - 2 years ago

Wedbush's Laura Chico talks biotech investing in 2024

EWTX NBIX VRDN XBI


Buy or bail on biotech: Here's what you need to know

Dec 26, 2023, 1:40 PM EST - 2 years ago

Buy or bail on biotech: Here's what you need to know

XBI


Wells Fargo's top pharma picks for 2024

Dec 15, 2023, 5:33 PM EST - 2 years ago

Wells Fargo's top pharma picks for 2024

ABBV AMGN BIIB LLY REGN VRTX


How to Find the Best Biotech ETFs

Oct 30, 2023, 4:52 PM EDT - 2 years ago

How to Find the Best Biotech ETFs

ARKG XBI


hegdaom
hegdaom May. 13 at 1:15 AM
$CAPR shorts? time to reload before you get liquidated again!!!! $XBI $IBB
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle May. 12 at 4:49 PM
Makari resigning Tuesday https://www.google.com/url?q=https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014&sa=U&ved=2ahUKEwi-_YylmrSUAxU4hIkEHZLXMx0QFnoECAkQAg&usg=AOvVaw1F8xpU5WBva0-aBGc8elg- $IBB $XBI $KNSA
0 · Reply
flabb
flabb May. 12 at 1:51 PM
$IBB limit orders in 168.28 and 167.72
0 · Reply
hegdaom
hegdaom May. 12 at 1:29 AM
0 · Reply
macroaxis
macroaxis May. 11 at 10:42 PM
$IBB — Option volatility signal: iShares Biotechnology pin risk is easing. https://www.macroaxis.com/stock-options/IBB/iShares-Biotechnology-ETF?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
ripztrip
ripztrip May. 11 at 6:37 PM
$IDYA WHY the Lag Exists Several factors explain why the stock hasn't yet priced in the full upside despite bullish data: Topline ≠ Full Data: The April 13 release was just topline PFS data. The ASCO presentation on June 1 will deliver depth-of-response, subgroup analyses, durability, and safety granularity — details that regulators and physicians need, and that drive NDA filings. "Buy the rumor, sell the news" risk: Some traders may have taken gains after the April 13 pop, creating a reset opportunity before ASCO $XBB $IBB
2 · Reply
PickAlpha
PickAlpha May. 11 at 11:59 AM
3/6: MoonLake (MLTX) reports positive final pre‑BLA FDA meeting for sonelokimab (SLK) in hidradenitis suppurativa; plans BLA submission end‑Sep 2026 and seeks Priority Review. $MLTX $XBI $IBB $REGN $VRTX
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 11 at 3:26 AM
$VERA valuation & revenue multiples v 17 peer commercial-stage bios acquired just before/after FDA approval. The average peer 5-year revenue multiple was 1.35X &/or a 0.37X 10-year multiple. If VERA analyst consensus revenue estimates are credible AND if VERA were worth ab average 5 & 10-year multiples consistent with the 17 peers (2 HUGE IFs) that would come to $4.2-$4.4B in enterprise value. Adding VERA's $500MM net cash/debt would be $4.7-$4.9B in market cap. Using VERA's 3/31/26 cap table, that would come to $59-$62 per fully diluted share. This is a simple "what-if" as we're trying to learn more. Just to be clear, we have no idea what VERA might be worth in an acquisition. We also are unaware if VERA's gross margin profile will be consistent with these peers. This is not investment advice. Can any VERA investor comment on Atacicept's projected gross margin profile (as a subq injection) &/or speculate on whether or not VERA could fetch a premium M&A revenue multiple? $XBI $IBB
2 · Reply
BluntForceOptions
BluntForceOptions May. 11 at 12:21 AM
$IBB Q2 2026 Biotech Catalyst Outlook: 88 Major Data Readouts & Regulatory Milestones We're heading into a serious density of clinical data. If you’re in the trenches with these clinical-stage names, you know the next two months are essentially a gauntlet of binary events. The schedule is packed: 88 total catalysts, including 26 for May and 20 for June. I’m sharing this for those interested in a clear view of the upcoming calendar. It’s not an exhaustive list of every micro-cap ticker, but it covers the heart of the sector's upcoming volume. FWIW... trading this sector successfully requires looking past the mainstream narratives. I find it’s best to ignore the surface-level chatter and stick to a disciplined process of clinical and fundamental due diligence. Respect to everyone grinding through the data. Wishing you all the best... may your discipline be rewarded with the outcomes you’ve worked so hard to achieve. 🙏🏻 $XBI $CYTK $PFE $LLY - Source data: BiopharmIQ
0 · Reply
hegdaom
hegdaom May. 10 at 11:10 PM
$CAPR The near-term fight: Preliminary Injunction Capricor filed both its complaint and a preliminary injunction brief on May 7, 2026. This is the critical near-term battleground. In New Jersey Chancery (where the case was filed), preliminary injunction hearings are typically scheduled within a few weeks to a couple of months. Given the urgency — the FDA PDUFA date is August 22, 2026 — Capricor will argue strenuously for an expedited hearing. If the court grants the injunction before that date, Capricor could potentially distribute the drug on its own pending the full trial $XBI $IBB
0 · Reply
GordoHLYK13
GordoHLYK13 May. 10 at 9:57 PM
$AIM sentiment is reaching a boiling point after major clinical wins and fresh funding. Ampligen just delivered a 50% ORR, 79% clinical benefit rate, and 32.5-month survival in ovarian cancer with no severe toxicities — a huge validation for the platform. Now the market is watching the upcoming pancreatic cancer Phase 3 setup and June DURIPANC update as potential game-changers. Bulls see the recent pullback from the $4.2M warrant exercise as a shakeout before the next move higher. With short interest elevated, momentum building, and biotech eyes locked on the next catalyst, many believe sub-$1 $AIM could become a major valuation catch-up play if the pancreatic data keeps delivering. $MRK $TMO $AIM $XBI $IBB
0 · Reply
hegdaom
hegdaom May. 10 at 4:22 PM
$CAPR this is a process folks. Based on speaking to a few legal colleagues in New Jersey, could be around 4-6 weeks for a resolution on emergency injunctive relief. NS IMHO has zero leverage and little to no chance of winning. I would like to hear other prospectives though if you have other information. $SRPT $XBI $IBB
1 · Reply
clan
clan May. 10 at 1:20 PM
$MNKD Tune in. Buy in. Breathe in. Cash in. Mannkind Corp. 👀 $SPY $IBB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 10 at 12:31 AM
We'd been looking for a good $RIGL peer for a hypothetical M&A exit valuation in light of the CPRX acquisition. As we understand it, Tavalisse loses patent protection 7/27/2032 that manifests in lower analyst consensus thereafter. @DCZ The best peer or comp transaction we could find is $ICPT that, our records indicate, was acquired by Alfasigma for an EV of $800MM (Sept 2023). The graph compares RIGL 10-year analyst consensus (FY26 - 35) to ICPT's mgmt/BOD prepared 10-year revenue forecast (FY24 - 33). Revenue multiples are provided at the bottom. It's important to note ICPT sales were essentially at 100% margins where RIGL FY25 actual gross margin was 82% (i.e. Gavreto royalties). This is not investment advice. We have no idea what RIGL might be worth in a hypothetical M&A exit. We're merely sharing an analysis. $XBI $IBB
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 9 at 2:01 AM
$SNDX fully diluted shares, market cap & enterprise value using SNDX's 3/31/26 cap table. Also attached is a comparison of SNDX's valuation related revenue multiples v 15 peer comm'l-stage M&A exits. These may or may not be good peers/comps for SNDX. You decide for yourself. Note the median peer 5-year M&A revenue multiple = 0.90X. If SNDX 5-year analyst consensus is credible AND if SNDX was acquired for a 0.90X 5-year multiple (2 HUGE IFs) then SNDX would hypothetically be worth $3.4B in M&A EV (MC slightly higher). This would be ~$34.50 per share using SNDX's 3/31/26 cap table. Would SNDX merit a higher multiple from $INCY since SNDX's revenue forecast reflects collaboration revenues at 25-30% of Niktimvo sales? Would any other acquirer pay a premium multiple? We do not find SNDX FY31-32 revenue estimates to be credible but if they were & SNDX was acquired for the median peer 7-year multiple of 0.56X that would be $4.2B in EV, a much bigger number This is not investment advice. $XBI $IBB
1 · Reply
StocktwitsNews
StocktwitsNews May. 9 at 12:26 AM
ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost $ABCL $IBB $SPDW https://stocktwits.com/news/equity/markets/abcl-stock-clocks-best-week-since-february-on-clinical-data-anticipation-baker-bros-stake-boost/cZX37RpRegA
0 · Reply
Bio_investor_
Bio_investor_ May. 8 at 5:29 PM
$AXSM $XBI $IBB May be they should make it peak sales from 8Billion to 10 billion now. https://www.reuters.com/business/healthcare-pharmaceuticals/kennedys-health-officials-explored-us-ban-some-widely-used-antidepressants-2026-05-08/ This news is highly positive for Axsome Therapeutics (NASDAQ: AXSM), acting as a powerful macro-level tailwind for their flagship drug, Auvelity. Auvelity is NOT an SSRI (The Target of the Federal Push)
1 · Reply
hegdaom
hegdaom May. 8 at 5:10 PM
$CAPR appears to be a new court filing this hour pushing it higher? any links? $SRPT $XBI $IBB
0 · Reply
flabb
flabb May. 8 at 4:49 PM
$IBB 170.50 added
0 · Reply
hegdaom
hegdaom May. 8 at 3:17 PM
$CAPR We expect and assumed volatility. Thanks for the cheap shares! $XBI $IBB
0 · Reply
OrvalCrossfield
OrvalCrossfield May. 8 at 2:00 PM
$IBB biotech breadth matters, holding the range keeps rotation on watch
0 · Reply
hegdaom
hegdaom May. 8 at 1:44 PM
$CAPR Retail got stopped out last night. thats why its very dangerous to set stop loss orders in the after hours!!!! $SRPT $XBI $IBB $IDYA
0 · Reply